Introduction: Who Should Be Tested and When

Dry age-related macular degeneration, often called dry AMD, is a condition that develops gradually as people grow older. Because the earliest stage rarely produces symptoms that a person would notice on their own, many individuals discover they have the condition only during a routine eye examination. This makes regular screening especially important for certain groups of people.^[1]

People over the age of 50 should prioritize getting comprehensive eye exams at regular intervals, as this age group faces higher risk. The likelihood of developing dry AMD increases with each passing decade. If you are 55 or older, your eye care provider may recommend more frequent checkups to monitor any changes in your macula, the central part of the retina responsible for sharp, straight-ahead vision.^[3]

Family history plays a significant role in determining who should seek testing. If a parent or sibling has had macular degeneration, your own risk increases noticeably. In these cases, beginning eye exams earlier than age 50 might be advisable. Additionally, people who smoke, have high blood pressure, or eat diets high in saturated fats should consider themselves at higher risk and discuss appropriate screening schedules with their eye doctor.^[5]

Even if you feel your vision is perfectly fine, regular eye exams remain essential. Caucasian individuals, women, and people with cardiovascular disease or diabetes also face increased odds of developing dry AMD. Being overweight or having high cholesterol adds to the list of factors that make screening more urgent. Your eye care provider can assess your personal risk and recommend how often you should return for follow-up exams.^[6]

If you notice any changes in your vision—such as straight lines appearing wavy, difficulty reading in dim light, colors seeming less vibrant, or a blurry spot near the center of your visual field—you should contact your eye doctor right away, even if your next scheduled exam is months away. While these symptoms might indicate intermediate or late-stage dry AMD, they could also signal the development of wet AMD, a more severe form that progresses more quickly.^[2]

Diagnostic Methods for Identifying Dry AMD

Diagnosing dry age-related macular degeneration involves a combination of discussions about your health history, thorough eye examinations, and specialized imaging techniques. The process is generally painless and helps your eye care provider understand the extent and stage of the condition.

Medical and Family History Review

Your eye doctor will start by asking questions about your general health, any vision changes you have noticed, and whether anyone in your family has had macular degeneration. They may also inquire about lifestyle factors such as smoking, diet, and other medical conditions like high blood pressure or heart disease. This background information helps the doctor assess your risk level and tailor the examination accordingly.^[9]

Comprehensive Eye Examination

The core of diagnosing dry AMD is a detailed eye exam. Your eye doctor will place drops in your eyes to dilate the pupils, which allows them to see the back of the eye more clearly. Dilation temporarily makes your pupils larger so that light can enter more easily, giving the doctor a better view of the retina and macula.^[9]

Once your eyes are dilated, the doctor uses a special magnifying instrument called a slit lamp to examine the retina. They look for tiny yellow deposits under the retina known as drusen. Drusen are protein and fat buildup that can accumulate as the eye ages. In the early stages of dry AMD, small drusen may be present without causing any vision problems. As drusen grow larger or become more numerous, the condition may progress to intermediate or late stages.^[6]

The doctor will also check for changes in the appearance of the macula, such as a mottled look or areas where cells have started to waste away. In advanced dry AMD, known as geographic atrophy, noticeable patches of tissue breakdown can appear. These areas have sharp borders and represent parts of the macula that are no longer functioning properly.^[6]

Amsler Grid Testing

A simple tool called the Amsler grid is often used to detect changes in central vision. The grid looks like a sheet of graph paper with a dot in the center. You focus on the dot and describe whether any of the lines appear wavy, broken, blurry, or missing. People with intermediate or late-stage dry AMD may see distortions in the grid pattern. This test is quick and can be done at home as well, allowing patients to monitor their own vision between doctor visits.^[9]

Optical Coherence Tomography (OCT)

Optical coherence tomography, often shortened to OCT, is an imaging technique that creates detailed cross-sectional pictures of the retina. It works somewhat like an ultrasound, but instead of sound waves, it uses light waves to capture images. OCT scans can reveal the thickness of the retina, the presence of drusen, and areas where the macula has thinned or developed atrophy. This technology is particularly useful for tracking changes over time and determining the stage of dry AMD.^[2]

OCT is non-invasive and painless. You simply sit in front of the machine and look at a target while it scans your eye. The entire process takes only a few minutes, and the images provide valuable information that helps your doctor decide on the best course of action.^[6]

Fluorescein Angiography

In some cases, your eye doctor may recommend a test called fluorescein angiography. This involves injecting a special dye into a vein in your arm. The dye travels through your bloodstream and eventually reaches the blood vessels in your eyes. A camera then takes a series of photographs as the dye highlights the blood vessels in the retina. This test can reveal abnormal blood vessel growth or leakage, which is more common in wet AMD, but it can also help detect changes related to dry AMD.^[9]

While fluorescein angiography is generally safe, some people may experience mild side effects such as temporary skin discoloration or nausea. Your doctor will explain the procedure and answer any questions you have beforehand.

Indocyanine Green Angiography

Another imaging test, indocyanine green angiography, works similarly to fluorescein angiography but uses a different type of dye. This test may be performed alongside fluorescein angiography to provide additional details about the blood vessels beneath the retina. It is less commonly needed for diagnosing dry AMD alone but can be helpful in complex cases where the doctor needs a more complete picture.^[9]

Distinguishing Dry AMD from Other Conditions

Several eye conditions can cause symptoms similar to dry AMD, such as blurry central vision or difficulty reading. Your eye doctor will use the combination of tests described above to rule out other possibilities. For example, wet AMD involves abnormal blood vessels that leak fluid, which can be seen on OCT scans or angiography. Other conditions, like diabetic retinopathy or retinal vein occlusion, have distinct patterns that can be identified during the examination.^[7]

If drusen are found along with areas of thinning in the macula but no evidence of abnormal blood vessels or fluid leakage, the diagnosis is typically dry AMD. The size and number of drusen, along with any pigmentary changes or atrophy, help determine the stage of the disease—early, intermediate, or late.^[6]

Diagnostics for Clinical Trial Qualification

People with dry AMD may have the opportunity to participate in clinical trials testing new treatments. Clinical trials are research studies designed to evaluate whether a new drug, device, or intervention is safe and effective. To enroll in a trial, patients must meet specific criteria, and diagnostic tests play a central role in determining eligibility.

Baseline Vision and Retinal Assessment

Before joining a clinical trial, participants undergo a series of tests to establish a baseline—a starting point that researchers can compare to later measurements. These tests typically include a comprehensive eye exam, visual acuity testing (reading letters on a chart to measure how well you can see), and OCT scans to document the current state of the retina and macula.^[11]

Researchers need to know the exact stage of your dry AMD, the extent of drusen buildup, and whether any geographic atrophy is present. This information helps them select participants whose condition matches the goals of the study. For example, some trials may focus on early-stage dry AMD, while others target late-stage disease with geographic atrophy.

Exclusion of Wet AMD and Other Eye Diseases

Most clinical trials for dry AMD require that participants do not have wet AMD or other eye conditions that could interfere with the study results. Fluorescein angiography or OCT scans are used to confirm that there is no abnormal blood vessel growth or fluid leakage. If these signs are present, the patient may not be eligible for a dry AMD trial but could be considered for a wet AMD study instead.^[11]

Other eye diseases, such as glaucoma or diabetic retinopathy, may also disqualify someone from certain trials if they could affect the measurements or outcomes being studied. Your trial coordinator will explain which conditions are acceptable and which are not.

Monitoring Changes Over Time

Once enrolled in a clinical trial, participants return for regular follow-up visits. At each visit, the same diagnostic tests are repeated to track any changes in vision or the appearance of the retina. OCT scans, visual acuity tests, and sometimes additional imaging are used to measure whether the treatment being tested has any effect on slowing the progression of dry AMD.^[11]

Specialized Imaging and Biomarker Testing

Some advanced clinical trials may use specialized imaging techniques or look for biological markers in the blood or eye to better understand how dry AMD develops and progresses. For example, researchers might measure levels of certain proteins or inflammatory markers that are thought to play a role in the disease. These tests are not part of routine clinical care but can provide valuable information for developing new therapies.^[11]

Informed Consent and Screening Process

Before any testing begins, potential participants go through an informed consent process. This means the research team explains the purpose of the trial, what tests will be done, the potential risks and benefits, and the participant’s rights. Only after understanding and agreeing to these terms can someone officially enroll in the study.

The screening process may take several visits to complete. During this time, the research team ensures that the participant meets all eligibility criteria and that it is safe for them to take part. If someone does not qualify, the team may be able to suggest other trials or resources that might be helpful.